CombiMatrix Corporation Selects Cartagenia BENCHlab CNV Platform to Bolster Expanded Lab Operations

 CombiMatrix Corporation Selects Cartagenia BENCHlab CNV Platform to Bolster
                           Expanded Lab Operations

Growing Clinical Laboratory to Use BENCH to Increase Throughput of Microarray
Reporting

PR Newswire

BOSTON, Nov. 1, 2012

BOSTON, Nov. 1, 2012 /PRNewswire/ -- Cartagenia, the world leader in providing
genetic labs and clinicians software-based workflow support for variant
assessment, lab reporting, and integration of diagnostic knowledge-bases,
announced today that it has signed a license agreement for the Cartagenia
BENCHlab CNV platform with CombiMatrix Corporation (Nasdaq: CBMX), a molecular
diagnostics company.

Irvine, CA-based CombiMatrix is a CLIA-certified and CAP-accredited,
publicly-owned commercial clinical laboratory offering DNA-based genomic
testing services in the areas of prenatal and pediatric developmental
disorders and oncology. CombiMatrix has established itself as an industry
leader in microarray-based clinical testing via a core team of
microarray-pioneering physicians, scientists and technicians and has a strong
commitment to both client and patient-focused service.

BENCH will be used for the analysis, interpretation and reporting of
microarray results in routine postnatal and prenatal settings. The flexible
nature of the BENCH platform will allow it to be tailored to CombiMatrix's
variant assessment and reporting workflow, significantly accelerating the
interpretation and reporting process without disrupting the established
operating procedures. Additionally, BENCH's architecture will allow
integration and communication with existing IT systems at CombiMatrix.

Richard D. Hockett, Jr., M.D.,Chief Medical Officer at CombiMatrix remarked,
"With our lab operations and test volumes growing, it made perfect sense to
select the Cartagenia BENCH platform at this time. We already perform hundreds
of microarray analyses per month and having recently expanded testing for the
prenatal marketplace, that number will grow even more. The automation provided
by BENCHlab CNV gives us the ability to grow our array throughput while
providing significant savings in both analysis and interpretation time and
staffing. Another deciding factor was that Cartagenia clearly positions its
solutions for clinical use in contrast to other software packages."

"We are pleased and excited to be working with CombiMatrix," said Drew Arnold,
Cartagenia's VP of Sales, North America. "Its selection of the BENCH platform
is a strong validation of our approach and indicative of the efficiencies that
BENCH can bring to diagnostic laboratories."

Cartagenia successfully went through the process of implementing an
ISO-certified quality management system and has registered the BENCH platform
for variant interpretation and reporting as a Class 1 Medical Device with the
FDA.

"We want to provide a 'clinical grade' tool set to our customer and help labs
building a reliable infrastructure for clinical use of high-throughput genomic
technologies," Arnold added.

About Cartagenia

Cartagenia supplies diagnostic software, database systems, and related
services to genetic labs and clinicians, enabling them to perform clinically
relevant genetic analyses quickly and efficiently, and offer patients and
careers high-quality genetic interpretation and counseling.

The Cartagenia BENCH platform is built in collaboration with genetics labs and
clinical experts involved in routine medical practice. Because of this,
BENCHlab CNV addresses the specific needs of genetic diagnostic labs and
clinicians.

Cartagenia BENCHlab CNV is built using a certified ISO13485 Quality Management
System and is marketed as an FDA regulated Class I Medical Device in the
United States and as a Class I Medical Device in Europe in conformity with the
essential requirements and provisions of the Council Directive 93/42/EEC
concerning medical devices, and with the relevant harmonized standards EN
ISO62304.

www.cartagenia.com

AboutCombiMatrix Corporation

CombiMatrix Corporation, through its wholly owned subsidiary,CombiMatrix
Molecular Diagnostics, Inc.(CMDX), is a molecular diagnostics laboratory that
offers DNA-based testing services to the prenatal, pediatric and oncology
markets.The Company performs genetic testing utilizing Microarray, FISH, PCR
and G-Band Chromosome Analysis.CMDX offers prenatal and pediatric testing
services for the detection of abnormalities of genes at the DNA level beyond
what can be identified through traditional technologies.CMDX was also the
first commercial clinical laboratory inthe United Statesto make
comprehensive DNA-based genomic analysis of solid tumors, including breast,
colon, lung, prostate and brain tumors, available to oncology patients and
medical professionals.Additional information about CMDX is available at
www.cmdiagnostics.com or by calling 1-800-710-0624.

Contact:
CARTAGENIA
Herman Verrelst
CEO Cartagenia
Technologielaan 3
3001 Leuven
T +32 16 40 40 66
E herman.verrelst@cartagenia.com
www.cartagenia.com

ALLEN & CARON
Len Hall
VP Media Relations
T 1 949 474 4300
E len@allencaron.com
www.allencaron.com

SOURCE Cartagenia

Website: http://www.cartagenia.com
Website: http://www.cmdiagnostics.com
 
Press spacebar to pause and continue. Press esc to stop.